The record
| Class | musculoskeletal |
|---|---|
| Also known as | FS-344, FST-344, Follistatin 344, FS344 |
| Chain length | - |
| Molecular weight | 38,000 Da |
| Half-life | Not well-characterized for peptide |
| Route | SC (peptide) or IM (AAV gene therapy) |
| Studied for | - |
| Research use | Muscle hypertrophy studies; Myostatin inhibition research; Muscle wasting models |
| What has been shown | Muscle hypertrophy and hyperplasia; Reduced fat mass; Improved insulin sensitivity; Decreased fibrosis |
| How it works | Secreted glycoprotein that binds and neutralizes myostatin (GDF-8), activins, and some BMPs. Forms irreversible complexes with ligands (2:1 ratio), leading to internalization and degradation. FS-344 produces FS-315 after signal peptide cleavage, which has low heparin binding and circulates systemically (unlike FS-288 which localizes to gonads). Removes the "brake" on muscle growth by blocking myos |
| Patent status | Various patents |
| Regulatory status | Research only - NOT approved |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 64%)
- GH Pulsatility Environment (affection, 32%)
- Anti-fibrotic Signaling Environment (affection, 73%)
- Adult GH deficiency (illness, 30%)
- Anti-aging therapy (illness, 30%)
- Cardiac repair after myocardial infarction (illness, 40%)
- Duchenne muscular dystrophy (illness, 60%)
- Muscle wasting conditions (illness, 48%)
- Neuromuscular diseases (illness, 60%)
- Pediatric growth hormone deficiency (illness, 30%)
- Post-injury muscle recovery (illness, 40%)
- Post-stroke recovery (illness, 40%)
- Soft tissue repair (illness, 40%)
- Muscle loss or weakness (symptom, 67%)